{"downloaded": true, "htmlmade": false, "full": {"id": "29976746", "source": "MED", "pmid": "29976746", "pmcid": "PMC6165825", "fullTextIdList": {"fullTextId": "PMC6165825"}, "doi": "10.3324/haematol.2018.189514", "title": "Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.", "authorString": "Burnett AK, Das Gupta E, Knapper S, Khwaja A, Sweeney M, Kjeldsen L, Hawkins T, Betteridge SE, Cahalin P, Clark RE, Hills RK, Russell NH, UK NCRI AML Study Group.", "authorList": {"author": [{"fullName": "Burnett AK", "firstName": "Alan K", "lastName": "Burnett", "initials": "AK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Formerly Department of Haematology, Cardiff University School of Medicine, UK akburnett719@gmail.com."}}}, {"fullName": "Das Gupta E", "firstName": "Emma", "lastName": "Das Gupta", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Nottingham University Hospital NHS Trust, UK."}}}, {"fullName": "Knapper S", "firstName": "Steve", "lastName": "Knapper", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, University Hospital of Wales, Cardiff, UK."}}}, {"fullName": "Khwaja A", "firstName": "Asim", "lastName": "Khwaja", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University College, London Cancer Institute, UK."}}}, {"fullName": "Sweeney M", "firstName": "Marion", "lastName": "Sweeney", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, University Hospital of Wales, Cardiff, UK."}}}, {"fullName": "Kjeldsen L", "firstName": "Lars", "lastName": "Kjeldsen", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Rigshospitalet, Copenhagen, Denmark."}}}, {"fullName": "Hawkins T", "firstName": "Timothy", "lastName": "Hawkins", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Auckland City Hospital, New Zealand."}}}, {"fullName": "Betteridge SE", "firstName": "Sophie E", "lastName": "Betteridge", "initials": "SE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Centre for Trials Research, Cardiff University School of Medicine, UK."}}}, {"fullName": "Cahalin P", "firstName": "Paul", "lastName": "Cahalin", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Blackpool Victoria Hospital, UK."}}}, {"fullName": "Clark RE", "firstName": "Richard E", "lastName": "Clark", "initials": "RE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Royal Liverpool University Hospital, UK."}}}, {"fullName": "Hills RK", "firstName": "Robert K", "lastName": "Hills", "initials": "RK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Royal Liverpool University Hospital, UK."}}}, {"fullName": "Russell NH", "firstName": "Nigel H", "lastName": "Russell", "initials": "NH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Nottingham University Hospital NHS Trust, UK."}}}, {"collectiveName": "UK NCRI AML Study Group"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "10", "volume": "103", "journalIssueId": "2731953", "dateOfPublication": "2018 Oct", "monthOfPublication": "10", "yearOfPublication": "2018", "printPublicationDate": "2018-10-01", "journal": {"title": "Haematologica", "ISOAbbreviation": "Haematologica", "medlineAbbreviation": "Haematologica", "NLMid": "0417435", "ISSN": "0390-6078", "ESSN": "1592-8721"}}, "pubYear": "2018", "pageInfo": "1654-1661", "abstractText": "As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty-nine patients were randomised (2:1) to receive everolimus or not for a maximum of 84 days between chemotherapy courses. The primary endpoint was relapse-free survival. At 5 years there was no difference in relapse-free survival [29% <i>versus</i> 40%; odds ratio 1.19 (0.9-1.59) <i>P</i>=0.2], cumulative incidence of relapse [60% <i>versus</i> 54%: odds ratio 1.12 (0.82-1.52): <i>P</i>=0.5] or overall survival [45% <i>versus</i> 58%: odds ratio 1.3 (0.94-1.81): <i>P</i>=0.11]. The independent Data Monitoring Committee advised study termination after randomization of 339 of the intended 600 patients because of excess mortality in the everolimus arm without any evidence of beneficial disease control. The delivery of the everolimus dose was variable, but there was no evidence of clinical benefit in patients with adequate dose delivery compared with no treatment. This study suggests that the addition of mammalian target of rapamycin inhibition to chemotherapy provides no benefit.", "affiliation": "Formerly Department of Haematology, Cardiff University School of Medicine, UK akburnett719@gmail.com.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase III", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"]}, "grantsList": {"grant": {"grantId": "15954", "agency": "Cancer Research UK", "acronym": "CRUK_", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Adolescent"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "Y", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "TOR Serine-Threonine Kinases", "meshQualifierList": {"meshQualifier": {"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "Y", "descriptorName": "Consolidation Chemotherapy"}, {"majorTopic_YN": "N", "descriptorName": "Everolimus", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}]}, "chemicalList": {"chemical": [{"name": "MTOR protein, human", "registryNumber": "EC 2.7.1.1"}, {"name": "TOR Serine-Threonine Kinases", "registryNumber": "EC 2.7.1.1"}, {"name": "everolimus", "registryNumber": "9HW64Q8G6G"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3324/haematol.2018.189514"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6165825"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6165825?pdf=render"}]}, "commentCorrectionList": {"commentCorrection": {"id": "30270203", "source": "MED", "reference": "Haematologica. 2018 Oct;103(10):1579-1581", "type": "Comment in", "orderIn": "1"}}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "6", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-10-08", "dateOfCreation": "2018-07-07", "firstIndexDate": "2018-07-07", "fullTextReceivedDate": "2020-07-12", "dateOfRevision": "2019-10-08", "electronicPublicationDate": "2018-07-05", "firstPublicationDate": "2018-07-05"}, "htmllinks": "https://europepmc.org/articles/PMC6165825", "abstract": "As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty-nine patients were randomised (2:1) to receive everolimus or not for a maximum of 84 days between chemotherapy courses. The primary endpoint was relapse-free survival. At 5 years there was no difference in relapse-free survival [29% <i>versus</i> 40%; odds ratio 1.19 (0.9-1.59) <i>P</i>=0.2], cumulative incidence of relapse [60% <i>versus</i> 54%: odds ratio 1.12 (0.82-1.52): <i>P</i>=0.5] or overall survival [45% <i>versus</i> 58%: odds ratio 1.3 (0.94-1.81): <i>P</i>=0.11]. The independent Data Monitoring Committee advised study termination after randomization of 339 of the intended 600 patients because of excess mortality in the everolimus arm without any evidence of beneficial disease control. The delivery of the everolimus dose was variable, but there was no evidence of clinical benefit in patients with adequate dose delivery compared with no treatment. This study suggests that the addition of mammalian target of rapamycin inhibition to chemotherapy provides no benefit.", "pdflinks": "https://europepmc.org/articles/PMC6165825?pdf=render", "journaltitle": "Haematologica", "title": "Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial."}